

1 **Reproducible breath metabolite changes in children with SARS-CoV-2 infection**

2

3 Amalia Z. Berna¹, Elikplim H. Akaho¹, Rebecca M. Harris^{1,2,3}, Morgan Congdon^{1,3}, Emilie Korn^{1,3},
4 Samuel Neher^{1,3}, Mirna M'Farrej^{1,3}, Julianne Burns^{1,3}, Audrey R. Odom John^{1,3*}

5

6 ¹Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

7 ²Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia,
8 Philadelphia, Pennsylvania, USA

9 ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

10

11

12

13 ***Corresponding author:**

14 Audrey R. Odom John MD PhD

15 Department of Pediatrics

16 Children's Hospital of Philadelphia

17 Philadelphia, Pennsylvania, USA 19104

18 Phone: 215-590-2457

19 Email: (JOHNA3@email.chop.edu)

20

21 **ABSTRACT**

22 SARS-CoV-2 infection is diagnosed through detection of specific viral nucleic acid or antigens
23 from respiratory samples. These techniques are relatively expensive, slow, and susceptible to
24 false-negative results. A rapid non-invasive method to detect infection would be highly
25 advantageous. Compelling evidence from canine biosensors and studies of adults with COVID-
26 19 suggests that infection reproducibly alters human volatile organic compounds (VOCs)
27 profiles. To determine whether pediatric infection is associated with VOC changes, we enrolled
28 SARS-CoV-2-infected and -uninfected children admitted to a major pediatric academic medical
29 center. Breath samples were collected from children and analyzed through state-of-the-art
30 GCxGC-ToFMS. Isolated features included 84 targeted VOCs. Candidate biomarkers that were
31 correlated with infection status were subsequently validated in a second, independent cohort of
32 children. We thus find that six volatile organic compounds are significantly and reproducibly
33 increased in the breath of SARS-CoV-2-infected children. Three aldehydes (octanal, nonanal,
34 and heptanal) drew special attention, as aldehydes are also elevated in the breath of adults with
35 COVID-19. Together, these biomarkers demonstrate high accuracy for distinguishing pediatric
36 SARS-CoV-2 infection and support the ongoing development of novel breath-based diagnostics.

37

38

39 **Keyword:** SARS-CoV-2, COVID-19, breath, pediatrics, discovery, biomarkers

40 INTRODUCTION

41 Novel diagnostic strategies are urgently needed to control the current COVID-19 pandemic,
42 caused by infection with the novel coronavirus SARS-CoV-2. SARS-CoV-2 infection is typically
43 diagnosed through detection of viral specific nucleic acids or antigens from samples collected
44 from the upper respiratory tract (e.g. saliva, oropharyngeal, nasal, or nasopharyngeal swabs).
45 Such testing can be uncomfortable and relatively expensive, requires multiple reagents for
46 which supplies can be limited (swabs, viral transport media, and RNA extraction kits), and relies
47 on specialized laboratory equipment and trained personnel. Moreover, high false-negative rates
48 have been reported.¹ Improved access to simple, rapid diagnostic testing for SARS-CoV-2
49 infection would facilitate COVID-19 control efforts and support clinical care of symptomatic or
50 exposed individuals, especially in resource-limited environments. In addition, a rapid diagnostic
51 test suitable for large-scale screening of children for coronavirus infection could facilitate
52 infection prevention and control in congregate living or educational settings.

53

54 Children with SARS-CoV-2 infection typically experience mild symptoms of disease and are
55 much less likely to experience severe outcomes, such as hospitalization or death, as compared
56 to adults.² Children also exhibit a distinct immunological response to coronavirus infection.³⁻⁴
57 These clinical and immunological differences in children with SARS-CoV-2 suggest that their
58 metabolic response to infection may also be different than that of adults. However, any novel
59 diagnostic test for SARS-CoV-2 will require excellent performance characteristics in children,
60 due to the importance of testing in this population. Asymptomatic or mildly symptomatic
61 pediatric cases may transmit SARS-CoV-2 within the household or community.⁵ While adults
62 are inconvenienced by social distancing measures to control viral transmission, the educational
63 and social development of children may be irreparably harmed.⁶ Finally, until global control of
64 COVID-19 is achieved, children will continue to require a disproportionately high frequency of

65 testing, due to both the burden of clinically indistinguishable non-SARS-CoV-2 upper respiratory
66 viral infections in childhood (up to 12 per year) and the delayed availability of vaccination for
67 young children.⁷

68

69 Metabolic changes induced by respiratory infections may alter host odor profiles, such that
70 infection-associated volatile organic compounds (VOCs) may be used to develop noninvasive
71 diagnostics through sensor arrays (e.g. “breathalyzers”) or electronic noses. Promising proof-of-
72 concept comes from studies of other respiratory infections that lead to characteristic alterations
73 in breath metabolite profiles, including infection with *Mycobacterium tuberculosis*⁸ and
74 *Aspergillus* spp., as well as ventilator-associated pneumonia.⁹ Viral respiratory pathogens
75 impact host volatile production *in vitro* and *in vivo*. For example, infection with either rhinovirus¹⁰
76 or influenza in cell culture¹¹ results in reproducible VOC changes. Similarly, studies in an animal
77 model of influenza infection demonstrate an increase in breath concentrations of acetaldehyde,
78 propanal, and n-propyl acetate.¹² More recently, compelling evidence from canine biosensors
79 suggests that volatile detection may be a promising approach for SARS-CoV-2 diagnosis.
80 Trained dogs reproducibly recognize SARS-CoV-2 infection in saliva/tracheal samples¹³, urine¹⁴
81 and sweat samples.¹⁵ In addition, distinct breath signatures were found in adult patients with
82 COVID-19, compared to those with unrelated respiratory and cardiac conditions.¹⁶ Preliminary
83 studies using sensor arrays confirm that SARS-CoV-2 infection in adults likewise results in
84 distinct breath volatile changes.¹⁷

85

86 To evaluate whether changes in breath metabolites also characterize the exhaled breath of
87 pediatric patients with SARS-CoV-2 infection, we analyzed breath metabolite profiles from two
88 independent cohorts of children with and without SARS-CoV-2, who were admitted to a major
89 pediatric academic medical center (for workflow, see Supplemental Figure 2). Through targeted

90 GCxGC-mass spectrometric analysis of 84 breath volatiles, we established candidate
91 biomarkers of pediatric SARS-CoV-2 infection, which were validated in an independent cohort of
92 children.

93

94 **RESULTS AND DISCUSSION**

95 Biomarker discovery was performed from breath metabolic profiling of pediatric patients (n=26)
96 from the Children's Hospital of Philadelphia (CHOP), 11 of whom were positive and 15 of whom
97 were negative for SARS-CoV-2 by nasopharyngeal (NP) RT-PCR. One SARS-CoV-2-infected
98 subject was excluded due to poor quality of breath sampling.

99

100 Demographic and clinical characteristics in this discovery cohort are shown in Table 1. SARS-
101 CoV-2-infected and -uninfected patients were broadly similar with respect to age, sex, and
102 racial/ethnic characteristics. Individuals infected with SARS-CoV-2 were more likely to exhibit
103 either fever (50% vs. 0.0%, p=0.004) or cough (40% vs. 0.0%, p=0.016), compared to
104 uninfected subjects. Two SARS-CoV-2-positive subjects (25%) lacked symptoms of acute
105 infection (specifically fever, sore throat, cough, or GI symptoms). Two subjects with positive
106 nasopharyngeal testing for SARS-CoV-2 were subsequently diagnosed with multisystem
107 inflammatory syndrome in children (MIS-C), believed to be a late complication of SARS-CoV-2
108 infection.

109

110 For each patient, breath volatiles were captured onto sorbent material and subsequently
111 released by thermal desorption for analysis by two-dimensional gas chromatography and time-
112 of-flight mass spectrometry (GCxGC ToF-MS). Isoprene is one of the most common and
113 abundant human breath VOCs. To establish the quality of breath VOC collection, the

114 abundance of isoprene was compared to the abundance of isoprene in ambient air, which had
115 been collected in the same room and at the same time as breath collection. For each subject,
116 we find that the abundance of isoprene was markedly higher than ambient levels, confirming
117 successful breath VOC collection (Supplementary Figure 3).

118

119 For our targeted metabolite analysis, we selected 84 VOCs that have previously been identified
120 as either common human odorants¹⁸, associated with host response to viral infection, or were
121 found to be elevated in the breath of adults with COVID-19.^{10-12, 16, 19-20} Volcano plots (Figure 1a)
122 were used to visualize breath metabolic features that distinguished SARS-CoV-2-infected from -
123 uninfected individuals, using $p < 0.05$ as a threshold for statistical significance. Six candidate
124 breath biomarkers were significantly elevated in the breath of children with SARS-CoV-2
125 infection: three aldehydes [octanal, nonanal, and heptanal (Figure 2)], as well as decane,
126 tridecane, and 2-pentyl furan (Figure 1b and Supplementary Figure 4). All compound identities
127 were confirmed by comparison to pure commercial standards. Analytical characteristics of
128 candidate breath biomarkers can be found in Supplementary Table 1.

129

130 Heat map visualization indicates an increase in the abundance of candidate volatile biomarkers
131 in the breath of children with SARS-CoV-2 infection (Figure 1b), suggesting that SARS-CoV-2
132 infection alters the overall profile of breath VOCs. Because elevated temperature alone can alter
133 metabolic profiles, we evaluated whether any candidate biomarkers correlated with fever. We
134 find that fever was not associated with significant changes in abundance of any SARS-CoV-2
135 biomarker (Supplementary Figure 5).

136

137 To establish the reproducibility of these candidate biomarkers, independent subjects were
138 enrolled in a validation cohort of children with and without SARS-CoV-2 infection (n=24).
139 Patients enrolled had similar demographic and clinical characteristics as the discovery cohort,
140 and infected and uninfected children were broadly similar (Table 1). We found that all candidate
141 SARS-CoV-2 biomarkers were increased in abundance in infected, compared to uninfected,
142 children in this validation cohort (Supplementary Figure 6). To visualize the discriminatory power
143 of these biomarkers, principal components analysis (PCA) was performed (Figure 3). This
144 technique indicates substantial differences in breath volatile composition in the validation cohort
145 between SARS-CoV-2-infected children compared to children without infection. Using the sum
146 of the abundances of these 6 biomarkers (“cumulative abundance”) as a diagnostic strategy, we
147 evaluated its diagnostic characteristics. A receiver operating characteristic (ROC) curve yielded
148 an area under the curve (AUC) of 0.92, providing a sensitivity of 91% and specificity of 75%
149 (Figures 4a, b and c). Overall, our results suggest that SARS-CoV-2 infection leads to
150 characteristic and reproducible changes in breath volatiles in children, and that as few as 6
151 volatiles may be used to diagnose SARS-CoV-2 with high accuracy.

152
153 Compared to adults, children have a distinct immune response and are less likely to become
154 seriously ill with SARS-CoV-2 infection. For this reason, biomarkers enriched in the breath of
155 adults with symptomatic COVID-19 may be distinct from those in children. We investigated
156 whether breath volatiles that were previously found to be associated with adult COVID-19 were
157 also present in our pediatric samples.¹⁶ We find that two medium-chain aldehydes that are
158 elevated in the breath of adults with COVID-19, octanal and heptanal, are also elevated in the
159 breath of children with SARS-CoV-2 infection (Figure 2b). Interestingly, pediatric SARS-CoV-2
160 infection was also associated with increased levels of a third aldehyde, nonanal. In contrast, two
161 chemically distinct breath biomarkers of SARS-CoV-2 infection in adults, acetone and 2-

162 butanone, are not significantly altered in SARS-CoV-2-infected children, compared to uninfected
163 controls (Figure 5 and supplementary Figure 7).

164

165 Frequent, rapid testing has been proposed as an important public health strategy for control of
166 the current COVID-19 pandemic. An easy-to-use SARS-CoV-2 “breathalyzer” based on
167 electronic nose technologies or sensor arrays would have a turnaround time of minutes and
168 would not strain supply chains of specialized disposable supplies. Because of ongoing
169 advances in portable, low-cost, field-stable sensor array platforms that may be harnessed for a
170 VOC-based diagnostic, there is enthusiastic industry support that may rapidly translate volatile
171 biomarkers into physical devices for point-of-care testing or screening.

172

173 Strong evidence indicates that SARS-CoV-2 infection in adults leads to a unique human odorant
174 profile. Canine biosensors (sniffer dogs) accurately recognize SARS-CoV-2 infection in
175 biological samples and have begun to be deployed for human screening in real-world settings
176 such as airports and sports arenas.^{13, 15} Previous studies by Ruszkiewicz et al¹⁶ also report
177 breath biomarkers associated with COVID-19 in adults presenting for emergency room
178 evaluation with acute respiratory symptoms. They find that breath biomarkers distinguished
179 patients with COVID-19 from those with other respiratory conditions with high (>80%) accuracy.

180 ¹⁶ Metabolites, including breath volatile organic compounds, that are associated with viral
181 infection are most likely to arise from changes in host metabolism, raising the possibility that
182 populations that differ in their clinical response to infection might also have divergent metabolic
183 profiles. Since pediatric SARS-CoV-2 infection is generally mild and less likely to result in
184 serious respiratory symptoms, we expected that the breath metabolic biomarkers of children
185 infected with SARS-CoV-2 might differ from those found in adults. In this work, we provide
186 compelling support that SARS-CoV-2 infection leads to characteristic volatile organic compound

187 changes in the breath of children, as it does in adults. However, we find that the breath volatile
188 signature of pediatric SARS-CoV-2 is distinct. For example, pediatric SARS-CoV-2 infection
189 does not lead to changes in some specific breath biomarkers, such as acetone and 2-butanone,
190 that are highly characteristic of COVID-19 in adults.

191

192 This work provides important validation that SARS-CoV-2 infection leads to changes in breath
193 aldehyde concentrations in both children and adults. The prior study by Ruszkiewicz et al¹⁶
194 found that increased levels of two aldehydes, octanal and heptanal, were present in the breath
195 of adults with SARS-CoV-2 infection, compared to those with other acute respiratory illnesses
196 (such as COPD and pneumonia). We find that octanal, heptanal, and the structurally similar
197 aldehyde nonanal, are all significantly elevated in the breath of children with SARS-CoV-2
198 infection, suggesting a common biological origin for this class of SARS-CoV-2-associated
199 breath volatiles. Altogether our studies highlight the need to include pediatric samples in early
200 discovery efforts to develop new and much-needed diagnostics for SARS-CoV-2, in order to
201 identify biomarkers that are shared across all relevant populations.

202

203 SARS-CoV-2-associated breath biomarkers that are shared by adults and children may reflect a
204 more generalized host response to viral infection. For this reason, an important limitation of
205 contemporary biomarker discovery efforts for COVID-19, including our study, is the relatively
206 reduced incidence of non-SARS-CoV-2 circulating respiratory viruses due to interventions such
207 as school closures, masking, and social distancing. Other viral infections may induce host
208 aldehyde production, an observation that has been attributed to infection-associated cellular
209 oxidative stress that leads to oxidation of unsaturated fatty acids and accumulation of by-
210 products.^{21-22,23} For example, in a study of influenza A-induced breath volatiles, the breath
211 abundance of acetaldehyde, propanal, and n-propyl acetate increased during acute infection

212 and decreased as infection resolved.¹² More recently, *in vitro* studies have demonstrated that
213 infection with the seasonal coronavirus HCoV-229E leads to a significant increase in the levels
214 of cellular fatty acids.²⁴ Viral infections outside the respiratory tract may trigger similar metabolic
215 changes, as fecal volatiles from children with rotavirus gastroenteritis were enriched in 2,3-
216 butanedione, octanal, nonanal, and 2-heptenal, compared to samples from children without
217 rotavirus infection.²⁵ Understanding the biological origin of viral-induced aldehydes will be
218 crucial to establishing the specificity and clinical utility of SARS-CoV-2-associated biomarkers.

219

220 **CONCLUSIONS**

221 Increasing evidence suggests that SARS-CoV-2 infection in adults is associated with specific
222 changes in volatile production. This study provides additional support that the breath abundance
223 of six volatile organic compounds (including aldehydes) are altered in children with SARS-CoV2
224 infection. Importantly, most SARS-CoV-2-infected subjects enrolled demonstrated mild
225 symptoms of infection and were only incidentally found to be infected due to routine pre-
226 admission screening at our institution. Given the cost, discomfort, and false-negative results
227 associated with RT-PCR- or antigen-based tests, breathalyzer testing for SARS-CoV-2 may
228 provide an inexpensive, non-invasive, rapid, and highly sensitive alternative for population-
229 based frequent screening of children.

230

231 **METHODS**

232 **Study Approval and Enrollment**

233 Prior to enrollment, the study was approved by the Children's Hospital of Philadelphia (CHOP)
234 Human Research Ethics Committee (IRB 20-017503) and by the CHOP Institutional Biosafety
235 Committee (IBC 19-000145) for handling of human samples potentially containing SARS-CoV-2.

236 Breath samples were collected from children (4-18 years of age) hospitalized in the Special
237 Isolation Unit at CHOP, who had been diagnosed as SARS-CoV-2 positive by nasopharyngeal
238 swab RT-PCR on admission (n=11). Samples from uninfected individuals were obtained from
239 nasopharyngeal RT-PCR-negative subjects, enrolled from the Emergency Department
240 Extended Care Unit of the Children's Hospital of Philadelphia (n=15). Samples were collected
241 between June and August 2020. The viral load of patient nasopharyngeal swab samples was
242 estimated by cycle threshold value (Ct-value) of the N gene, with lower Ct-values indicating a
243 higher viral load. Samples were considered positive if the Ct-value was ≤ 40 , and Ct values of
244 positive test results were obtained (Table 1). For validation studies, we collected an additional
245 set of samples from SARS-CoV-2-infected children (n=12) and from SARS-CoV-2-uninfected
246 individuals (n=12). Samples were collected as above from CHOP between October 2020 and
247 March 2021. The sample size for this cohort was based on a calculated effect size of 1.5
248 between SARS-CoV-2-infected and -uninfected samples for the 6 biomarkers, which predicted
249 that 12 samples in each group would yield a power ($1 - \beta$ error prob) of 0.97 ($p < 0.05$).

250

251 Exclusion criteria for control subjects included current rhinorrhea, cough, or diarrhea, in order to
252 exclude individuals that may have false negative SARS-CoV-2 testing. In addition, subjects
253 were excluded if they required oxygen supplementation within 3 hours of breath sample
254 collection. Samples were not screened for common circulating non-SARS-CoV-2 human
255 coronaviruses or other viral respiratory pathogens.

256

257 **Breath sample collection**

258 Breath collection was performed as previously described²⁶⁻²⁷. In brief, SARS-CoV-2-infected and
259 -uninfected subjects exhaled through a disposable cardboard mouthpiece connected to a

260 chamber. The chamber was then attached using tubing to a 3-L SamplePro FlexFilm sample
261 bag (SKC Inc, Pennsylvania) (Supplementary Figure 1). The volunteers were asked to take a
262 few deep breaths, place the cardboard tube between the lips, and exhale completely. Neither a
263 nose clip nor VOC filter were used. Breath from the bags was transferred to a sorbent tube as
264 previously described^{26, 28}. Briefly, 1 L of the breath sample was transferred to sorbent tube at
265 200 mL min⁻¹ using an electric pump, so that all tubes had consistently the same volume. Three-
266 bed Universal sorbent tubes containing Tenax, Carbograph, and Carboxen were used (Markes
267 International Limited, UK). For each participant, ambient air samples and breath samples were
268 collected from the same room. Samples were stored at 4°C until the time of analysis (within 2
269 weeks of collection). Samples were analyzed using thermal desorption and GCxGC BenchTOF-
270 MS (SepSolve Analytical, UK). Analytical parameters are described in Supplementary Material.

271

272

273

274 **AUTHOR CONTRIBUTIONS**

275 **Amalia Z. Berna.** Project coordinator, assisted with ethical approval, recruitment, sample
276 collection, instrumental analysis, data interpretation and writing the manuscript.

277 **Elikplim H. Akaho.** Assisted with ethical approval, recruitment, sample collection and revision
278 of the manuscript

279 **Rebecca M. Harris.** Assisted with data collection and revision of manuscript

280 **Morgan Congdon.** Sample collection, revision of manuscript.

281 **Emilie Korn.** Sample collection, revision of manuscript

282 **Samuel Neher.** Sample collection, revision of manuscript

283 **Mirna M'Farrej.** Assisted with subject recruitment, revision of manuscript

284 **Julianne Burns.** Sample collection, clinical coordination with the Special Isolation Unit, revision
285 of manuscript and ethical approval

286 **Audrey R. Odom John.** Study conception, study design, assisted with ethical approval, data
287 interpretation, and manuscript writing.

288 **ACKNOWLEDGMENTS**

289 This work was supported by the National Institutes of Health [grant numbers: R61-DH105594,

290 R01-AI103280, R21-AI123808, and R21-AI130584], and AOJ is an Investigator in the

291 Pathogenesis of Infectious Diseases (PATH) of the Burroughs Wellcome Fund. We express our

292 gratitude to the children and families of the Children's Hospital of Philadelphia for all their

293 support and participation. We acknowledge the unique efforts of the front-line clinical staff to

294 facilitate breath collection.

REFERENCES

1. Wang, Y.; Kang, H.; Liu, X.; Tong, Z., Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. *Journal of Medical Virology* **2020**, 92 (6), 538-539.
2. Li, X.; Xu, W.; Dozier, M.; He, Y.; Kirolos, A.; Theodoratou, E.; Uncover, The role of children in transmission of SARS-CoV-2: A rapid review. *J Glob Health* **2020**, 10 (1), 011101.
3. Diorio, C.; Henrickson, S. E.; Vella, L. A.; McNerney, K. O.; Chase, J.; Burudpakdee, C.; Lee, J. H.; Jasen, C.; Balamuth, F.; Barrett, D. M.; Banwell, B. L.; Bernt, K. M.; Blatz, A. M.; Chiotos, K.; Fisher, B. T.; Fitzgerald, J. C.; Gerber, J. S.; Gollomp, K.; Gray, C.; Grupp, S. A.; Harris, R. M.; Kilbaugh, T. J.; John, A. R. O.; Lambert, M.; Liebling, E. J.; Paessler, M. E.; Petrosa, W.; Phillips, C.; Reilly, A. F.; Romberg, N. D.; Seif, A.; Sesok-Pizzini, D. A.; Sullivan, K. E.; Vardaro, J.; Behrens, E. M.; Teachey, D. T.; Bassiri, H., Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. *The Journal of clinical investigation* **2020**, 130 (11), 5967-5975.
4. Weisberg, S. P.; Connors, T.; Zhu, Y.; Baldwin, M.; Lin, W. H.; Wontakal, S.; Szabo, P. A.; Wells, S. B.; Dogra, P.; Gray, J. I.; Idzikowski, E.; Bovier, F.; Davis-Porada, J.; Matsumoto, R.; Li Poon, M. M.; Chait, M. P.; Mathieu, C.; Horvat, B.; Decimo, D.; Bitan, Z. C.; La Carpia, F.; Ferrara, S. A.; Mace, E.; Milner, J.; Moscona, A.; Hod, E. A.; Porotto, M.; Farber, D. L., Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19. *medRxiv* **2020**.
5. NG, S.; AC, M.; A, M.; al., e. *Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering — Four States*; June–July 2020; pp 1457–1459.
6. Masonbrink, A. R.; Hurley, E., Advocating for Children During the COVID-19 School Closures. *Pediatrics* **2020**, 146 (3).
7. Nokso-Koivisto, J.; Pitkaranta, A.; Blomqvist, S.; Jokinen, J.; Kleemola, M.; Takala, A.; Kilpi, T.; Hovi, T., Viral etiology of frequently recurring respiratory tract infections in children. *Clin Infect Dis* **2002**, 35 (5), 540-6.
8. Phillips, M.; Basa-Dalay, V.; Blais, J.; Bothamley, G.; Chaturvedi, A.; Modi, K. D.; Pandya, M.; Natividad, M. P. R.; Patel, U.; Ramraje, N. N.; Schmitt, P.; Udwadia, Z. F., Point-of-care breath test for biomarkers of active pulmonary tuberculosis. *Tuberculosis* **2012**, 92 (4), 314-320.
9. Filipiak, W.; Beer, R.; Sponring, A.; Filipiak, A.; Ager, C.; Schiefecker, A.; Lanthaler, S.; Helbok, R.; Nagl, M.; Troppmair, J.; Amann, A., Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study. *J. Breath Res.* **2015**, 9 (1).
10. Schivo, M.; Aksenov, A. A.; Linderholm, A. L.; McCartney, M. M.; Simmons, J.; Harper, R. W.; Davis, C. E., Volatile emanations from in vitro airway cells infected with human rhinovirus. *J Breath Res* **2014**, 8 (3), 037110.
11. Purcaro, G.; Rees, C. A.; Wieland-Alter, W. F.; Schneider, M. J.; Wang, X.; Stefanuto, P. H.; Wright, P. F.; Enelow, R. I.; Hill, J. E., Volatile fingerprinting of human respiratory viruses from cell culture. *J Breath Res* **2018**, 12 (2), 026015.

12. Traxler, S.; Bischoff, A. C.; Sass, R.; Trefz, P.; Gierschner, P.; Brock, B.; Schwaiger, T.; Karte, C.; Blohm, U.; Schroder, C.; Miekisch, W.; Schubert, J. K., VOC breath profile in spontaneously breathing awake swine during Influenza A infection. *Sci Rep* **2018**, *8* (1), 14857.
13. Jendry, P.; Schulz, C.; Twele, F.; Meller, S.; von Kockritz-Blickwede, M.; Osterhaus, A.; Ebbers, J.; Pilchova, V.; Pink, I.; Welte, T.; Manns, M. P.; Fathi, A.; Ernst, C.; Addo, M. M.; Schalke, E.; Volk, H. A., Scent dog identification of samples from COVID-19 patients - a pilot study. *Bmc Infect Dis* **2020**, *20* (1), 536.
14. Essler, J. L.; Kane, S. A.; Nolan, P.; Akaho, E. H.; Berna, A. Z.; DeAngelo, A.; Berk, R. A.; Kaynaroglu, P.; Plymouth, V. L.; Frank, I. D.; Weiss, S. R.; Odom John, A. R.; Otto, C. M., Discrimination of SARS-CoV-2 infected patient samples by detection dogs: A proof of concept study. *PLoS One* **2021**, *16* (4), e0250158.
15. Grandjean, D.; Sarkis, R.; Tourtier, J.-P.; Julien-Lecocq, C.; Benard, A.; Roger, V.; Levesque, E.; Bernes-Luciani, E.; Maestracci, B.; Morvan, P.; Gully, E.; Berceau-Falancourt, D.; Pesce, J.-L.; Lecomte, B.; Haufstater, P.; Herin, G.; Cabrera, J.; Muzzin, Q.; Gallet, C.; Bacqué, H.; Broc, J.-M.; Thomas, L.; Lichaa, A.; Moujaes, G.; Saliba, M.; Kuhn, A.; Galey, M.; Berthail, B.; Lapeyre, L.; Méreau, O.; Matteï, M.-N.; Foata, A.; Bey, L.; Philippe, A.-S.; Abassi, P.; Pisani, F.; Delarbre, M.; Orsini, J.-M.; Capelli, A.; Renault, S.; Bachir, K.; Kovinge, A.; Comas, E.; Stainmesse, A.; Etienne, E.; Voeltzel, S.; Mansouri, S.; Berceau-Falancourt, M.; Leva, B.; Faure, F.; Dami, A.; Costa, M. A.; Tafanelli, J.-J.; Luciani, J.-B.; Casalot, J.-J.; Charlet, L.; Ruau, E.; Issa, M.; Grenet, C.; Billy, C.; Desquillet, L., Detection dogs as a help in the detection of COVID-19 Can the dog alert on COVID-19 positive persons by sniffing axillary sweat samples ? Proof-of-concept study. *bioRxiv* **2020**, 2020.06.03.132134.
16. Ruszkiewicz, D. M.; Sanders, D.; O'Brien, R.; Hempel, F.; Reed, M. J.; Riepe, A. C.; Bailie, K.; Brodrick, E.; Darnley, K.; Ellerkmann, R.; Mueller, O.; Skarysz, A.; Truss, M.; Wortelmann, T.; Yordanov, S.; Thomas, C. L. P.; Schaaf, B.; Eddleston, M., Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry - a feasibility study. *EClinicalMedicine* **2020**, *29* (100609).
17. Shan, B.; Broza, Y. Y.; Li, W.; Wang, Y.; Wu, S.; Liu, Z.; Wang, J.; Gui, S.; Wang, L.; Zhang, Z.; Liu, W.; Zhou, S.; Jin, W.; Zhang, Q.; Hu, D.; Lin, L.; Zhang, Q.; Li, W.; Wang, J.; Liu, H.; Pan, Y.; Haick, H., Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. *Acs Nano* **2020**, *14* (9), 12125-12132.
18. de Lacy Costello, B. D.; Amann, A.; Al-Kateb, H.; Flynn, C.; Filipiak, W.; Khalid, T.; Osborne, D.; Ratcliffe, N. M., A review of the volatiles from the healthy human body. *J. Breath Res.* **2014**, *8* (1).
19. Aksenov, A. A.; Sandrock, C. E.; Zhao, W.; Sankaran, S.; Schivo, M.; Harper, R.; Cardona, C. J.; Xing, Z.; Davis, C. E., Cellular scent of influenza virus infection. *Chembiochem* **2014**, *15* (7), 1040-8.
20. Traxler, S.; Barkowsky, G.; Sass, R.; Klemenz, A. C.; Patenge, N.; Kreikemeyer, B.; Schubert, J. K.; Miekisch, W., Volatile scents of influenza A and *S. pyogenes* (co-)infected cells. *Sci Rep-Uk* **2019**, *9*.
21. Schwarz, K. B., Oxidative stress during viral infection: a review. *Free Radic Biol Med* **1996**, *21* (5), 641-9.

22. Ratcliffe, N.; Wieczorek, T.; Drabinska, N.; Gould, O.; Osborne, A.; De Lacy Costello, B., A mechanistic study and review of volatile products from peroxidation of unsaturated fatty acids: an aid to understanding the origins of volatile organic compounds from the human body. *J Breath Res* **2020**, *14* (3), 034001.
23. Ayala, A.; Munoz, M. F.; Arguelles, S., Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev* **2014**, *2014*, 360438.
24. Yan, B.; Chu, H.; Yang, D.; Sze, K. H.; Lai, P. M.; Yuan, S.; Shuai, H.; Wang, Y.; Kao, R. Y.; Chan, J. F.; Yuen, K. Y., Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. *Viruses* **2019**, *11* (1).
25. Al-Kateb, H. In *Analysis of faecal volatiles from young children infected with or without Rotavirus*, 2012.
26. Berna, A. Z.; DeBosch, B.; Stoll, J.; John, A. R. O., Breath Collection from Children for Disease Biomarker Discovery. *Jove-J Vis Exp* **2019**, (144).
27. Berna, A. Z.; McCarthy, J. S.; Wang, X. R.; Michie, M.; Bravo, F. G.; Cassells, J.; Trowell, S. C., Diurnal variation in expired breath volatiles in malaria-infected and healthy volunteers. *J. Breath Res.* **2018**, *12* (4).
28. Berna, A. Z.; McCarthy, J. S.; Wang, R. X.; Saliba, K. J.; Bravo, F. G.; Cassells, J.; Padovan, B.; Trowell, S. C., Analysis of breath specimens for biomarkers of *Plasmodium falciparum* infection. *J. Infect. Dis.* **2015**, *212* (7), 1120-1128.

Table 1. Demographics. Patient demographics and clinical characteristics

Variables	Discovery cohort			Validation cohort		
	SARS-CoV-2 negative (n = 15)	SARS-CoV-2 positive (n = 10)	p value	SARS-CoV-2 negative (n = 12)	SARS-CoV-2 positive (n = 12)	p value
Demographic characteristics						
Age (years), median (IQR)	15 (12-16)	11 (8.2-17)	0.15	15 (14-16)	12.5 (9.25-15.75)	0.022
Female, n (%)	9 (60)	6 (60)	>0.99 ¹	9 (75)	6 (50)	>0.40 ¹
Black or African-American, n (%)	6 (40)	5 (50)	0.69 ¹	5 (42)	4(33)	>0.99 ¹
BMI/Age percentile, median (IQR)	86 (62.5-98) ²	61.5 (45-84)	0.11	26 (21-31)	19 (17-26) ³	0.09
Reported Symptoms, n (%)						
Fever (>38.0°C)	0 (0)	5 (50)	0.004 ¹	0(0)	2(17)	0.47 ¹
Cough (new onset or worsening of chronic cough)	0 (0)	4 (40)	0.016 ¹	0(0)	0(0)	>0.99 ¹
Sore throat	0 (0)	1 (10)	0.40 ¹	0 (0)	1(8)	>0.99 ¹
Headache	0 (0)	1 (10)	0.40 ¹	0 (0)	1(8)	>0.99 ¹
Laboratory						
Cycle threshold values (SARS-CoV-2 RT-PCR), median (IQR)	>40 (negative)	36.74 (31.78-37.63)	---	>40 (negative)	28.83 (22.15-32.92) ⁴	---

Data represent median value (interquartile range) or number of patients (%).

¹ Fisher's exact test used for contingency table analysis. ² Data unavailable for two patients. ³ Data unavailable for one patient.

⁴ Data unavailable for four patients.




Figure 1. Candidate breath biomarkers of pediatric SARS-CoV-2 infection. (a) Volcano plot of breath metabolites. Fold change = mean abundance SARS-CoV-2-infected/mean abundance uninfected. Purple, breath metabolites significantly different ($p < 0.05$) in SARS-CoV-2-infected subjects compared to uninfected. Metabolite identities are shown in heat map. (b) Heat map visualizing abundance of breath biomarkers (presented as z-scores) in a discovery cohort of uninfected- and SARS-CoV-2-infected pediatric subjects.




Figure 2. Pediatric SARS-CoV-2 infection is associated with an increased abundance of breath

aldehydes. (a) Three-dimensional GCxGC ToF-MS surface plots of two representative pediatric breath samples (top, SARS-CoV-2-infected; bottom, SARS-CoV-2-uninfected), demonstrating increased abundance of characteristic medium-chain aldehydes (†, heptanal; ‡, octanal; *, nonanal) associated with SARS-CoV-2 infection. 1tR, retention time in minutes; 2tR, retention time in seconds. (b) Scatter plot of breath abundance of candidate SARS-CoV-2 aldehyde biomarkers in uninfected and infected children.

Octanal and heptanal were also previously found to be increased in abundance in the breath of adults with COVID-19¹⁶. Median and quartiles are shown. P-values (t-tests) are shown for each comparison.




Figure 3. Discriminatory power of candidate SARS-CoV-2 breath biomarkers in an independent

cohort of children. Principal component analysis was performed with six candidate biomarkers of SARS-CoV-2 using breath samples from an independent validation cohort of children with and without SARS-CoV-2 infection.




Figure 4. Performance characteristics of a cumulative abundance metric for SARS-CoV-2 diagnosis.

(a) The cumulative abundance (normalized to internal standard) of six candidate biomarkers readily distinguishes breath profiles from an independent validation cohort of children with and without SARS-CoV-2 infection (t-test, $p=0.001$). The cumulative abundance is the sum of abundances of the six candidate biomarkers. (b) Distribution of cumulative abundance of biomarkers from SARS-CoV-2- infected and uninfected children. Red line, threshold of discrimination between infected and uninfected. (c) Receiver operator characteristics (ROC) curve for the cumulative abundance of 6 biomarkers. Dotted line indicates expected results if predictive power is no better than random chance. Using threshold, this cumulative abundance metric yields 91% sensitivity and 75% specificity.




Figure 5. Ketones associated with adult COVID-19 are not enriched in the breath of children with SARS-CoV-2 infection. Acetone and 2-butanone were previously reported to be enriched in the breath of adults with COVID-19 ¹⁶. No significant differences were found between SARS-CoV-2 infected and uninfected pediatric samples in the pilot data (shown). Similar results were observed in an independent validation cohort (Supplementary Figure 7). Median and quartiles are shown. P-values (t-tests) are shown for each comparison.